$103.41
+2.29 (+2.26%)
At Close: Jun 12, 2026
Why SoFi Technologies Rose 22.2% in May
10:52pm, Sunday, 05'th Jun 2022 The Motley Fool
After a brutal start to the year, the fintech stock had a solid earnings report, followed by positive analyst notes and an insider purchase from the CEO.
Why the Sun Was Shining on SolarEdge Stock Today
09:12pm, Thursday, 02'nd Jun 2022 The Motley Fool
That's what often happens when an analyst makes a big recommendation upgrade.
Why Shares of Enphase Energy Are Soaring Today
04:04pm, Wednesday, 27'th Apr 2022 The Motley Fool
This solar stock is electrifying investors' excitement after a strong earnings report.
2 Growth Stocks With Up to 187% Upside, According to Wall Street
12:12pm, Monday, 25'th Apr 2022 The Motley Fool
Are these stocks oversold? Some analysts certainly think so.
Why Netflix Stock Flopped Again Today
10:00pm, Thursday, 21'st Apr 2022 The Motley Fool
The company is hit with a tidal wave of analyst downgrades and price target cuts as investors continue to bail.
Why Twilio Stock Dived by 10% on Wednesday
09:57pm, Wednesday, 20'th Apr 2022 The Motley Fool
The latest analyst price-target cut didn't do the company any favors.
Why Shares of Coinbase Plunged Further Today
06:08pm, Monday, 18'th Apr 2022 The Motley Fool
Yet another analyst voices concerns about Coinbase's growing challenges.
Infographic: New Survey Shows Rising Consumer Interest In Buy Now, Pay Later Services
09:30pm, Friday, 15'th Apr 2022 Benzinga
More than 60% of Americans are more interested in Buy Now Pay Later (BNPL) than they were before the COVID-19 pandemic, according to a new survey from Opy and 72Point.
Openpay Group Ltd (ASX: OPY) is
Amgen Inc. (AMGN) Management Presents at Oppenheimer''s 32nd Annual Healthcare Conference 2022 (Transcript)
06:59pm, Wednesday, 16'th Mar 2022 Seeking AlphaWhy Coupa Software Stock Crumbled Again Today
10:50pm, Tuesday, 15'th Mar 2022 The Motley Fool
Big misses with guidance lead to a clutch of analyst price-target cuts, and even a pair of downgrades.
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer''s 32nd Annual Healthcare Conference (Transcript)
05:47pm, Tuesday, 15'th Mar 2022 Seeking AlphaBiomea Fusion to Present at Oppenheimer’s 32nd Annual Virtual Healthcare Conference
12:30pm, Tuesday, 15'th Mar 2022 GlobeNewswire
REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that it is scheduled to participate in a fireside chat at the Oppenheimer 32 nd Annual Virtual Healthcare Conference on Wednesday, March 16, 2022 at 7:00am Pacific Time. Thomas Butler, Biomea’s CEO and Chairman of the Board, will participate in the fireside chat.
DBV Technologies to Present at the Oppenheimer''s 32nd Annual Healthcare Conference
08:30pm, Monday, 14'th Mar 2022 Benzinga
Montrouge, France, March 14, 2022 DBV Technologies to Present at the Oppenheimer''s 32nd Annual Healthcare Conference DBV Technologies (GREY: DBVTF ), a clinical-stage biopharmaceutical company, today announced that Dr. Pharis Mohideen, Chief Medical Officer, will present at the Oppenheimer''s 32nd Annual Healthcare Conference on Thursday, March 17 th at 10:00 a.m. ET. A webcast of the presentation may be accessed by visiting the Investors & Media section of the DBV Technologies website at https://www.dbvtechnologies.com/investor-relations/ . An archived replay of the webcast … Full story available on Benzinga.com
Coinbase Has ‘Hidden Value’ in Ventures Business, Oppenheimer Says
05:30pm, Monday, 14'th Mar 2022 CoinDesk
Crypto exchange Coinbase’s stock is undervalued, the investment bank said in a note to clients.
McDonald''s is recommended at Oppenheimer with Russia-Ukraine risk already priced in
12:51pm, Monday, 14'th Mar 2022 Seeking Alpha
Oppenheimer recommended that investors buy McDonald''s MCD on any further weakness with the same-store sales strength expected. Read more on MCD stock.
Sign In
Buy OPY